[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338409-105":59,"doc-detail-338409-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","recent-advances-in-and-applications-of-ex-vivo-drug-sensitivity-analysis-for-blood-cancers-review-open-access","Recent advances in and applications of ex vivo drug sensitivity analysis for blood cancers - review open access","","Blood cancers, including leukemia, multiple myeloma, and lymphoma, remain difficult to treat due to strong biological heterogeneity and the limited specificity and toxicity profiles of conventional therapies. Precision medicine enables individualized treatment selection, and ex vivo drug sensitivity analysis supports this by testing patient-derived cancer cells against therapeutic panels to forecast clinical response. The review summarizes recent methodological progress, including improved drug-response metrics, evaluation of drug combinations, and ex vivo assessment of advanced agents such as antibody–drug conjugates, linking technical innovation to better personalized outcomes and updated standards of care.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/recent-advances-in-and-applications-of-ex-vivo-drug-sensitivity-analysis-for-blood-cancers-review-open-access/338409/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/recent-advances-in-and-applications-of-ex-vivo-drug-sensitivity-analysis-for-blood-cancers-review-open-access/338409.png","ImageObject",300,407,{"name":92,"@type":93},"Eden","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are blood cancers challenging for traditional treatment approaches?","Question",{"text":112,"@type":113},"Blood cancers are heterogeneous, and standard therapies such as chemotherapy and radiation lack specificity and can cause toxicities, limiting effectiveness across patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does ex vivo drug sensitivity analysis support precision medicine?",{"text":117,"@type":113},"Patient-derived cancer cells are tested against a panel of therapeutic agents to predict clinical responses, helping identify effective options and investigate resistance mechanisms.",{"name":119,"@type":110,"acceptedAnswer":120},"What recent developments extend ex vivo drug sensitivity analysis beyond basic measures?",{"text":121,"@type":113},"The review highlights refined drug-response metrics such as AUC and drug sensitivity scores (DSS) and the use of machine learning to model complex datasets for improved prediction accuracy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338409,1790241404,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Lee et al. Blood Research (2024) 59:37 [https://doi.org/10.1007/s44313-024-00032-8](https://doi.org/10.1007/s44313-024-00032-8)  \nBlood Research  \n REVIEW Open Access  \nRecent advances in and applications of ex vivo drug sensitivity analysis for blood cancers  \nHaeryung Lee1†, Nahee Ko1†, Sujin Namgoong1†, Seunghyok Ham2 and Jamin Koo 1,2*  \nAbstract  \nBlood cancers, including leukemia, multiple myeloma, and lymphoma, pose significant challenges owing to their heterogeneous nature and the limitations of traditional treatments. Precision medicine has emerged as a transformative approach that offers tailored therapeutic strategies based on individual patient profiles. Ex vivo drug sensitivity analysis is central to this advancement, which enables testing of patient-derived cancer cells against a panel of therapeutic agents to predict clinical responses. This review provides a comprehensive overview of the latest advancements in ex vivo drug sensitivity analyses and their application in blood cancers. We discuss the development of more comprehensive drug response metrics and the evaluation of drug combinations to identify synergistic interactions. Additionally, we present evaluation of the advanced therapeutics such as antibody–drug conjugates using ex vivo assays. This review describes the critical role of ex vivo drug sensitivity analyses in advancing precision medicine by examining technological innovations and clinical applications. Ultimately, these innovations are paving the way for more effective and individualized treatments, improving patient outcomes, and establishing new standards for the management of blood cancers.  \nKeywords Drug sensitivity, Blood cancers, Precision medicine, Machine learning, Prognosis  \nIntroduction  \nBlood cancers, including leukemia, multiple myeloma (MM), and lymphoma, represent a significant burden on global health and affect several million patients worldwide [1]. Traditional treatment approaches for these malignancies, such as chemotherapy and radiation, often have limitations because of their lack of specificity and associated toxicities. In recent years, precision medicine has emerged as a transformative approach in oncology,  \n†Haeryung Lee, Nahee Ko and Sujin Namgoong contributed equally to this work.  \n*Correspondence:  \nJamin Koo [jaminkoo@alumni.stanford.edu](jaminkoo@alumni.stanford.edu)  \n1 Department of Chemical Engineering, Hongik University, Seoul 04066, Republic of Korea  \n2 ImpriMedKorea, Inc., Seoul 03920, Republic of Korea  \noffering the promise of more effective and personalized treatments tailored to individual patient profiles [2–4]. Central to this approach is the use of genotyping analysis to reveal the trait(s) of each patient’s tumor. More recently, the development and use of ex vivo drug sensitivity analysis have been reported, which allows the testing of patient-derived cancer cells against a panel of therapeutic agents to predict clinical responses [5–10]. This technology not only aids in identifying the most effective treatments for individual patients but also helps to understand resistance mechanism(s), thereby paving the way for more targeted and successful therapeutic strategies.  \nA critical challenge in ex vivo drug sensitivity analysis is to keep patient-derived cells alive and functionally intact outside the human body. Initial applications of this technology in blood cancers, particularly acute myeloid leukemia (AML), have demonstrated promising results  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicat","cbCaihEu4nXkfBze","https://ap.wps.com/l/cbCaihEu4nXkfBze","pdf",819483,"English","# Abstract\n# Introduction\n## Limitations of traditional treatments\n## Precision medicine and ex vivo assays\n## Key challenge: maintaining viable patient cells\n# Recent advancements in analysis metrics\n## Beyond IC50: AUC and DSS\n## Machine learning integration\n# Drug combinations and advanced therapeutics","[{\"question\":\"Why are blood cancers challenging for traditional treatment approaches?\",\"answer\":\"Blood cancers are heterogeneous, and standard therapies such as chemotherapy and radiation lack specificity and can cause toxicities, limiting effectiveness across patients.\"},{\"question\":\"How does ex vivo drug sensitivity analysis support precision medicine?\",\"answer\":\"Patient-derived cancer cells are tested against a panel of therapeutic agents to predict clinical responses, helping identify effective options and investigate resistance mechanisms.\"},{\"question\":\"What recent developments extend ex vivo drug sensitivity analysis beyond basic measures?\",\"answer\":\"The review highlights refined drug-response metrics such as AUC and drug sensitivity scores (DSS) and the use of machine learning to model complex datasets for improved prediction accuracy.\"}]","Recent advances in and applications of ex vivo drug sensitivity analysis for blood cancers - review open access | PDF",1790023527,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/382901e2819eae039845a93bffd674cf.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a25a887f2412f23a7873e8c7bd2e6c37.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/749740dc8f20a3ce833aa2c78e392e4c.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69f5de4d675eb46bc2486ea37048a6c3.webp",980,1301]